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Data accumulated over recent years have signiﬁcantly advanced our understanding of growth factors, cytokines, and hormones
in breast milk. Here we deal with leptin, adiponectin, IGF-I, ghrelin, and the more recently discovered hormones, obestatin, and
resistin, which are present in breast milk and involved in food intake regulation and energy balance. Little is known about these
compounds in infant milk formulas. Nutrition in infancy has been implicated in the long-term tendency to obesity, and a longer
duration of breastfeeding appears to protect against its development. Diet-related diﬀerences in serum leptin and ghrelin values
in infancy might explain anthropometric diﬀerences and diﬀerences in dietary habits between breast-fed and formula-fed infants
also later in life. However, there are still gaps in our understanding of how hormones present in breast milk aﬀect children. Here
we examine the data related to hormones contained in mother’s milk and their potential protective eﬀect on subsequent obesity.
Copyright © 2009 Francesco Savino et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Studies on the physiology of breastfeeding revealed the
presence of the two adipokines, leptin [1] and adiponectin
[2], hormones, such as IGF-I [3], ghrelin [4], and more
recently obestatin [5] and resistin [6] in mother’s milk
(Table 1). Human milk is a complex biological ﬂuid: leptin
and ghrelin are synthesized and secreted into breast milk
by the mammary gland and pass from serum into milk.
The origin of adiponectin, obestatin, and resistin remains
to be established. Leptin and ghrelin have a positive eﬀect
on the early control of satiety in infants and could inﬂuence
the programming of energy balance regulation in childhood
and adulthood thereby protecting against later obesity [7].
It is noteworthy that childhood obesity is associated with an
increased risk of adult metabolic syndrome [8].
Here, we review data related to hormones contained
in mother’s milk and their potential protective eﬀect on
subsequent obesity.
1.1. Leptin. Leptin is an adipocyte-derived hormone discov-
ered in 1994 [9]. It reduces appetite and increases energy
expenditure by acting on the arcuate nucleus in the hypotha-
lamus through its receptor (Ob-R) [10]. Circulating leptin
levels correlate with fat mass in adults and children [11].
Leptin is detectable in cord blood from the second trimester
of intrauterine life and correlates with adiposity at birth
[12]. Interestingly, serum leptin concentration correlates
with body mass index (BMI) in infants [13].
In obese subjects, endogenous leptin, even at high circu-
lating levels, fails to exert its normal eﬀects, and administra-
tion of exogenous leptin does not signiﬁcantly reduce adi-
posity. This condition, known as “leptin resistance”, could be
duetoreducedtransportofleptinintothebrainandreduced
expression of leptin receptor in the arcuate nucleus or an
increased concentration of SOCS3, which suppresses leptin
signaling by inhibiting leptin-induced STAT activation [14].
Leptin has been implicated in the neonatal development
of the hypothalamic pathways involved in the central regula-
tion of energy balance and appetite [15]. Studies conducted
in mice have shown that by acting on the brain during
a critical neonatal period that coincides with a naturally
occurring leptin surge, leptin promotes the formation of
neural circuits that control food intake and adiposity later
in life [16].
In humans, cord blood leptin concentration has been
observed to be inversely related to rates of intrauterine
growth, suggesting a possible role of leptin in promoting
fetus growth: small-for-gestational age (SGA) neonates have2 International Journal of Pediatric Endocrinology
Table 1: Breast milk hormones.
Hormone Year of
discovery Receptor
Detection of
receptor in
intestine
Main functions
Year of
discovery in
breast milk
Method of
detection in
breast milk
Detection in
umbilical
cord blood
Leptin 1994 Ob-receptor In humans [17] Anorexigenic eﬀect 1997 RIA [1, 18],
ELISA [16] [12, 19, 20]
Adiponectin 1995 Adipo-R1
Adipo-R2 In humans [21]
Improvement of
insulin sensitivity,
increase in fatty
acid metabolism,
anti-inﬂammatory
and
anti-atherogenic
properties
2006 RIA [2],
ELISA [22] [20]
Ghrelin 1999
Growth hormone
secretagogue
receptor -1a
In humans [23]
Orexigenic action;
stimulation of GH
secretion;
stimulation of acid
gastric secretion
and motility
2006 RIA [4, 24][ 25]
IGF-I 1950
IR IGF-IR IGF-IIR
Insulin
receptor-related
receptor IR-IGF-IR
hybrid receptor
In humans [26]
Primary mediator
of growth
hormone eﬀects;
role in the
regulation of
postnatal human
growth from late
infancy onward
1984 RIA [3]
Ib´ a˜ nez L
et al., 2008;
Lagiou P
et al., 2009
Resistin 2001 Unknown Unknown Regulation of
insulin sensitivity 2008 ELISA [6][ 27]
Obestatin 2005 GPR39 In mice [28] Anorexigenic
eﬀect? 2008 RIA [5] Unknown?
lower leptin levels at birth than appropriate-for-gestational
age (AGA) infants, and large-for-gestational age (LGA)
neonates have higher leptin levels than other infants [19].
Cord blood leptin seems to be a predictor of weight gain
also in later life; in fact lower cord blood leptin levels have
been observed to be associated with smaller size at birth but
more pronounced weight gain in the ﬁrst 6 months of life
and higher BMI at 3 years of age [20].
Leptin is present in human milk [1]; it is produced and
secreted by mammary epithelial cells in milk fat globules
[29]. Moreover, secretory epithelial cells may transfer leptin
from the blood to milk [30]. Leptin concentration was
found to be higher in whole than in skimmed samples of
h u m a nm i l k[ 18], probably because a portion of leptin could
be associated with the milk fat droplet or fat-associated
proteins. Leptin concentration was also higher in colostrum
than in transitional milk (4-5 days postpartum milk) [31].
Leptin receptors have been identiﬁed in gastric epithelial
cells and in the absorptive cells of mouse and human small
intestine [17], which suggests that leptin could pass from
milk to infant blood and might play a role in the short-
term regulation of feeding. This could occur during early
lactation. In fact, when neonatal rats were orally supplied
with leptin, the hormone was directly taken up by the
stomach thereby resulting in an increase in leptin levels in
the stomach and serum [32]. When these rats were fed a
chow or a high-fat diet from weaning, those that received
physiological doses of oral leptin during the suckling period
had a lower body weight and less adiposity in adulthood;
they also had greater insulin sensitivity and showed a
lower preference for fat-rich food than their controls [33].
Consequently, breast milk leptin could play a role in the
short-term control of food intake in neonates by acting
as a satiety signal and could also exert a long-term eﬀect
on energy balance and body weight regulation [34, 35].
Leptin concentrations in breast milk were found to correlate
positively with maternal circulating leptin levels, maternal
BMI, and the mother’s adiposity [36]. A positive correlation
has also been reported between breast milk leptin levels
and infant plasma leptin [37]. We observed higher serum
leptin concentrations in breast-fed infants than in formula-
fed babies in the ﬁrst months of life [38] and a positive
correlation between serum leptin concentration in breast-
fed infants and maternal BMI [39]. The presence of leptin in
the breast milk of nonobese mothers at 1 month of lactation
was found to be negatively correlated with infant BMI at 18
and 24 months of age [40]. Further studies are required to
better understand if leptin in human milk could play a role
indiﬀerencesinadiposity laterinlifeaccordingtothetypeof
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leptin and infant body composition may be present but still
remains an undeﬁned link [12].
Using radioimmunoassay, Lage et al. reported variable
leptin concentrations in commercial bovine milk and in
infant formulas [41]. However, according to O’Connor et
al., radioimmunoassay is not appropriate for the detection
of leptin in infant formulas because supplemented iron,
emulsiﬁers and other additives contained in formulas could
confound the assay [42]. Therefore, further research is
required to determine whether leptin is present in milk
formula.
1.2.Adiponectin. Adiponectinisthemostabundantadipose-
speciﬁc protein, and its multiple functions have only recently
started to emerge [43]. It was discovered in breast milk in
2006 by Martin et al. [2]a n dB r o n s k ye ta l[ 22]. Martin et
al. recently reported that adiponectin levels in human milk
decreased with the duration of lactation [2]. Adiponectin
circulates in very high concentrations in human serum and
its levels are inversely related to the degree of adiposity and
positively associated with insulin sensitivity. In fact, plasma
adiponectin concentrations are decreased in individuals with
obesity and type 2 diabetes [44].
Cord blood adiponectin levels have been observed to
be directly associated with birth weight for gestational age,
inversely associated with weight gain in the ﬁrst 6 months of
life, and to predict an increase in adiposity in 3 years old-
children [20].
Circulating adiponectin levels correlate negatively with
the degree of adiposity also in children aged between 5 and
10 years [45]. In contrast, in full-term infants during the
ﬁrst few days of life, serum and plasma adiponectin levels
correlate positively with birth weight and length, neonatal
adiposity, and circulating levels of leptin [46]. In preterm
infants, serum adiponectin levels are lower than in full-term
infants, correlate positively with body weight, and increase
with postnatal age, which suggests a metabolic adaptation
to premature extrauterine life [47]. Given the biological
propertiesofadiponectin, itspresenceinbreastmilk,andthe
expression of adiponectin receptor 1 in the small intestine
of neonatal mice [48] and of adiponectin receptor 1 and
2 in human colon epithelium [21], not only adiponectin
produced by adipose tissue but also milk adiponectin may
aﬀe c ti n f a n tg r o w t ha n dd e v e l o p m e n t .W e y e r m a n ne ta l .
found that higher levels of adiponectin in breast milk were
associated with overweight at two years of age in infants who
were breast-fed for at least 6 months [49]. Further research is
needed to evaluate whether exposure to adipokine in infancy
determines later weight status [50].
Bronskyetal.recentlydetectedinhumanbreastmilkalso
fatty acid binding proteins, which are produced by adipose
tissue and are related to lipid metabolism [22].
1.3. Resistin. Resistin was discovered in 2001 as a cytokine
secreted by adipocytes [51]. It was recently identiﬁed in
h u m a nm i l kb yI l c o le ta l .[ 6]. They found that resistin levels
decreasedduringlactation.Moreover,resistinconcentrations
in both milk and serum of breastfeeding mothers correlated
positively with hormone status (estradiol, progesterone,
prolactin, thyroxine, triiodothyronine, cortisol, and lep-
tin levels) and with concentrations of the inﬂammatory
parameter C-reactive protein. Lastly, they found that resistin
concentrationswerehigherintheserumofbreast-fedinfants
than in either breast milk or their mother’s serum [3].
Resistin was associated with insulin resistance in obese mice;
however homology between mouse and human resistin is
only 64%. Resistin has not been associated with insulin
resistance or obesity in humans, and the determination
of resistin as a marker of insulin resistance in children is
not recommended [52]. In the perinatal period, it seems
that resistin is not directly involved in the regulation of
insulin sensitivity or adipogenesis [53]. Circulating resistin
levels were found to be elevated in both genetic (ob/ob
and db/bd) and diet-induced mouse obesity and insulin-
resistance models [8] .T h er o l eo fr e s i s t i ni nf e t a la n d
infantile growth remains to be established. However, in this
context, it is known that umbilical serum resistin levels
correlate positively with maternal serum resistin levels and
negatively with neonatal birth weight [27]. This ﬁnding
suggests that resistin could have a role in controlling fetal
growth and, like the other breast milk hormones, could
be involved in appetite regulation and in the metabolic
development of infants.
1.4. Ghrelin. Ghrelin is a 28-amino-acid peptide produced
primarily in the stomach and so called for its property
of stimulating GH secretion in humans [54]. Signiﬁcant
ghrelin concentrations are present in human cord blood [25]
and ghrelin is a component of breast milk; it comes from
plasma [4] but also it is produced and secreted by the breast,
considering that ghrelin levels in breast milk are higher than
those found in plasma itself [24].
A portion of serum ghrelin possesses a fatty acid
modiﬁcation, an n-octanoylation, at the Ser 3 residue. This
acylated form, also known as “active ghrelin,” exerts the
same biological eﬀects as the hormone. Acylated ghrelin has
also been reported in breast milk; its concentrations increase
during lactation and are signiﬁcantly related with serum
ghrelin concentrations in breast-fed infants [55].
We identiﬁed a direct correlation between the circulating
level of ghrelin and age, weight, and length in infants in
the ﬁrst months of life and a negative correlation between
circulating ghrelin levels and weight gain only in infants who
have been breast-fed for at least four months, but not in
them who have been formula fed [56]. We also observed
higher ghrelin values in formula-fed infants [57] and, more
recently, a positive correlation between circulating ghrelin
levels and fasting time in the ﬁrst 6 months of life in infants
fed exclusively with formula [58].
Ghrelin stimulates food intake in rats and humans
[59] by acting primarily on the arcuate nucleus of the
hypothalamus. Ghrelin also exerts adipogenic activity, and
is involved in the long-term regulation of body weight [60].
Administration of ghrelin induced body weight gain and
adiposity in rodents by stimulating food intake and reducing
fat utilization and energy expenditure [61]. Considering
that ghrelin is involved both in short-term regulation of
food intake, by stimulating appetite, and in long-term4 International Journal of Pediatric Endocrinology
body-weight regulation, by inducing adiposity, the presence
of this hormone in breast milk could be one of the factors
through which breast-feeding may inﬂuence infant feeding
behavior and body composition later in life.
1.5. Obestatin. Obestatin, a 23-amino-acid peptide derived
from the ghrelin peptide precursor preproghrelin and pro-
duced by the human stomach, small intestine [62], and
salivary glands [63], was identiﬁed in breast milk by Aydin
and colleagues in 2008 [4]. They evaluated obestatin levels
in serum and milk from 31 lactating women on days 2
(colostrum) and 25 (mature milk) after delivery and found
higher hormone levels in milk than in blood: obestatin levels
in colostrum and mature milk were more than twice the
corresponding blood levels. It is not clear if obestatin comes
from the blood or breast but it may drain through the
mammary glands into the milk. The eﬀect of this hormone
is not well known. Some authors report that it reduces
food intake, body weight gain, and gastric emptying and
suppresses intestinal motility [4]. Obestatin is involved in
inhibiting thirst and anxiety, improving memory, regulating
sleep, inducing cell proliferation, and increasing exocrine
pancreatic secretion [64, 65]. Plasma obestatin levels are
increased in subjects with anorexia nervosa, in whom
obestatinseemedtobeamarkerofacuteandchronicchanges
in nutritional state [66]. The relationship between obestatin
and infant metabolic development merits further study.
1.6. Insulin-Like Growth Factor-I. IGF-I, a 70-amino acid
single chain polypeptide, is a member of a superfamily of
related insulin-like hormones, and it acts as the primary
mediator of growth hormone (GH) eﬀects. The 75% of
circulating IGF-I is produced by the liver, and postnatal
hepatic production is regulated by pituitary GH as well
as nutritional factors; it plays a role in the regulation of
postnatal human growth from late infancy onward [67].
I G F - Ia c t st h r o u g hd i ﬀerent receptors, that are the
insulin receptor (IR), IGF-IR, IGF-IIR, and several atypical
receptors, including the insulin receptor-related receptor
and the IR-IGF-IR hybrid receptor (composed of an IR
hemireceptor linked to an IGF-IR hemi-receptor) [68]. A
family of six high-aﬃnity IGF-binding proteins (IGFBP-1
through IGFBP-6) coordinate and regulate the biological
activity of IGF.
IGF-I levels decrease with sustained fasting and poor
nutritional status but are unaﬀected by recent food intake.
IGF-I plays a key role in both embryonic and post-
natal growth. Evidences from literature show a correlation
between IGF-I levels in cord blood and birth weight [69];
in particular, it has been demonstrated that children with
intrauterine growth retardation showed lower concentra-
tions than normal children [70].
Further, IGF-I levels in humans correlate with body
size; Klagsburn was the ﬁrst to show that human milk
contained growth factors that stimulated the growth of cells
in culture [71]. Baxter et al. demonstrated the presence of
IGF-I in human milk [3]; its levels are several-fold higher in
colostrum than in mature milk and they decrease in the ﬁrst
few days of lactation.
More recently, IGF-binding proteins (IGFBPs) have been
identiﬁed in human milk of term and preterm infants [72].
Infants fed with formula milk during the ﬁrst months of
life showed higher IGF-I levels than BF ones [57]. A recent
studyshowedapositivecorrelationbetweenIGF-Ivaluesand
Z score for weight, BMI, tricipital skin-fold thickness, and
age in healthy infants in the ﬁrst 5 months of life, sustaining
a possible programming of IGF-I axis during infancy [73].
2.BreastfeedingandObesity
Obesity is a relevant public health problem in both indus-
trialized and developing countries [74], especially because
of obesity-related chronic diseases. The rise in obesity has
been particularly steep in children. Overweight and obesity
result primarily from excess energy intake versus energy
expenditure [75]. The interaction between genetic factors
that determine susceptibility to weight gain and lifestyle [76]
(increased consumption of energy-dense foods and reduced
physicalactivity)isakeyfactorinthedevelopmentofobesity.
However, recent research suggests that long-term health
couldbedeterminedduringfetalandearlypostnatallife.The
relationship between low birth weight, catch-up growth dur-
ing the ﬁrst years of life, and the later occurrence of obesity,
insulin resistance, cardiovascular diseases, hyperlipidemia,
and type 2 diabetes has been amply documented [77, 78].
Experimental models and epidemiological studies suggest
that early nutrition is a key factor for the development
of obesity later in life, thereby supporting the concept of
“nutritional programming” [79]. In particular, breastfeeding
could play a key role in the programming process during
early life, but it is still diﬃcult to draw deﬁnitive conclusions
aboutthecausalrelationshipbetweenbreastfeedingandsuch
long-term health beneﬁts as prevention of obesity. A case-
controlstudybyKramerwasoneoftheﬁrststudiestosuggest
that breastfeeding exerts a protective eﬀect on later obesity
[80]. Because it is not ethical to perform randomized exper-
imental studies involving breastfeeding, the data available
come from observational studies, and confounding variables
remain an issue. Observational studies have conﬁrmed
an association between breastfeeding and reduced risk of
subsequent obesity, as shown in recent systematic reviews
[81, 82]. In particular, Harder et al. reported that prolonged
breastfeeding had a beneﬁcial eﬀect on the risk of overweight
in later life [83]. Armstrong et al. studied a large cohort
study of Scottish children and found that breastfeeding was
associated with a reduction in childhood obesity risk [84].
But, how does breastfeeding exert these beneﬁcial eﬀects?
The potential beneﬁts of breastfeeding on long-term obesity
and cardiovascular disease may be due to slower growth
in breast-fed infants compared to formula-fed infants [85].
The potential mechanisms by which breastfeeding protects
against rapid weight gain and consequently against later
obesity are the same as those that inﬂuence nutritional
behavior and those related to human milk composition.
From a behavioral viewpoint, because breast-fed babies can
self-control the amount of milk they consume, they may
learn to self-regulate their energy intake better than formula-
fedinfants[86],althoughitisnotclearifthiscouldinﬂuenceInternational Journal of Pediatric Endocrinology 5
nutritional behavior later in life. Moreover, parents who
choose to breast feed their babies generally have a healthier
lifestyle, and this tends to inﬂuence the lifestyle (including
diet and exercise) of oﬀspring. Diﬀerences in energy and
protein content between human milk and infant formula
might play a role in programming obesity risk: most infant
formulas have a slightly higher energy density and a higher
protein content than human milk [87]. A high protein intake
in infancy has been suggested to enhance the secretion of
insulin and IGF-I with a consequent stimulation of cell
proliferation, which promotes an accelerated growth and an
increased adipose tissue [88]. Epidemiologic studies shown
that high protein intake in early childhood was predictive of
an early occurrence of adiposity rebound [89]. In a recent
randomized clinical trial an association between a higher
protein content of infant formula and higher weight in the
ﬁrst two years of life has been reported [90].
Regarding the issue of human milk composition com-
pared to formula milk, breast milk contains bioactive
nutrients that are not present in formula milk [91].
It is known that human milk contains numerous growth
modulators, such as epidermal growth factor (EGF) [92],
insulin [93], and IGFs, which can stimulate gastrointestinal
mucosal proliferation and facilitate maturation and closure
of the neonatal gastrointestinal tract [94]. Receptors for
these growth factors have been found throughout the
gastrointestinal tract and these factors are relatively resistant
to proteolysis and remain stable in the gastrointestinal
tract [95]. Thus, many factors acting in concert aﬀect gut
maturation, leading gastrointestinal tract to change from an
organ of relatively high intestinal permeability to one of
selective permeability.
The recent identiﬁcation in breast milk of adipokines
and other hormones involved in energy balance regulation
suggests that breast milk may uniquely modulate neuroen-
docrine pathways involved in the regulation of body weight.
For leptin [17], adiponectin [48], IGF-I [26], obestatin [28],
and ghrelin [23] gastrointestinal receptors have been found,
even though it is still not well deﬁned if these hormones are
resistant to proteolysis and if these receptors can mediate
their absorption and action.
The presence of growth factors, enzymes, hormones, and
cytokinesgivestobreastmilkuniquepropertiesusefulforthe
maturating neonatal gut and for the metabolic development
of infants.
3. Concluding Remarks
Itislikelythatthenextfewyearswillseetheemergenceofthe
mechanisms by which early-life programming determines
the set-point of energy balance. One mechanism by which
breast-feeding may protect against the development of
childhood obesity is through the activity of components
of breast milk such as hormones involved in appetite and
energy balance that we describe in this review. Diﬀerences
in growth pattern and body composition between breast-
fed and formula-fed infants might be due to a diﬀerent
endocrine response to feeding or to bioactive substances
present in breast milk that could inﬂuence the infant’s
response to energy intake and metabolism [96]. However, we
are still far short of understanding the eﬀects on children of
hormonespresentinbreastmilk.Longitudinalinvestigations
will shed light on the new hormones discovered in mother’s
milk and their potential protective eﬀect on subsequent
obesity and metabolic-related disorders.
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